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Backgrounds: Bronchoalveolar lavage (BAL) is generally regarded as a safe diagnostic proce-
dure. However, acute exacerbation after BAL is increasingly recognized as a specific complica-
tion for patients with idiopathic pulmonary fibrosis (IPF). So far little is known about the
correlation between BAL and acute exacerbation of IPF (AE-IPF).
Methods: A cohort of 112 IPF patients at a single institution was analyzed retrospectively. We
defined BAL-related AE-IPF as development of AE-IPF within 30 days after the procedure. The
incidence rate of AE-IPF per person-month during the post-BAL period was compared with that
after the post-BAL period. The relative risk was estimated as the former rate divided by the
latter. We also reviewed the previous literature.
Results: Four AE-IPF cases occurred during the 201 person-month post-BAL period. The
risk of AE-IPF was significantly elevated within 30 days after BAL (rate ratio Z 4.12;
95% CI Z 1.03e12.2). None of the 111 initial BAL procedures were followed by AE-IPF within
a month. In a post hoc analysis, the relative risk of developing AE after second or later BAL
procedures was estimated to be considerably higher (rate ratioZ 9.10; 95% CIZ 2.27e26.98).
Twelve cases of BAL-induced AE-IPF were found in our study and in the literature review.
Among them, nine showed moderate to severe functional impairment, and eight had either
findings of leukocytosis, positive C-reactive protein, or neutrophilia in BAL.
Conclusions: These results suggest that IPF patients should be carefully monitored after BAL,
especially those with functional impairment or active inflammation.
ª 2011 Elsevier Ltd. All rights reserved.61 82 5101x7309; fax: þ81 561 82 9139.
d.biglobe.ne.jp (H. Taniguchi).
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Temporal relationship between BAL and acute exacerbation of IPF 437Introduction
our institution; cultures of blood and sputum for mycobac-Bronchoalveolar lavage (BAL) has been used in diagnostic
and prognostic evaluation in diffuse parenchymal lung
disease, and has a central role in the diagnosis of a number
of rare disorders and in excluding opportunistic infection in
treated patients.1 In diagnosing idiopathic pulmonary
fibrosis (IPF), the pattern of inflammatory cells identified in
BAL may be helpful in narrowing the differential diagnosis
of fibrosing interstitial pneumonias, but it is not in itself
diagnostic.2 Therefore, recent guidelines do not recom-
mend its routine use in diagnosing IPF.3,4 Nevertheless,
a recent study demonstrated that the addition of BAL to
diagnostic procedures is useful in patients suspected of
having IPF with a confident CT diagnosis.5 Moreover, BAL
cell differentials were reported to have prognostic value in
patients with IPF.6,7 BAL also remains an invaluable
research tool, providing information regarding immune
effector cells that accumulate in the alveolus and their
non-cellular products. This approach will continue to be
helpful in exploring the pathogenesis of the disease and is
widely used in the clinical setting.
BAL is generally regarded as a very safe procedure.8
Lethal complications are very rare and while minor
complications such as vasovagal reactions, fever, cardiac
arrhythmias, hemorrhage and pneumothorax have been
reported, most are considered self-limiting. In terms of IPF,
however, several cases in which there was progressive
degeneration of IPF after BAL have been reported.9e11
Therefore, along with surgical lung biopsy,12 some experts
suspect that BAL may be one of the precipitating factors for
developing acute exacerbation of IPF (AE-IPF).13
To date the correlation between BAL and AE-IPF remains
largely unknown. We conducted a retrospective cohort
study to investigate the temporal relationship between BAL
procedures and onset of AE-IPF. We further reviewed the
relevant literature to explore possible denominators of
BAL-induced AE-IPF patients.
Methods
This was a retrospective cohort study. Patients with IPF
diagnosed from April 1995 to December 2007 and subse-
quently followed at Tosei General Hospital (Seto, Aichi,
Japan) were eligible. The diagnosis of IPF was made
according to the American Thoracic Society (ATS)/European
Respiratory Society (ERS) Consensus Classification.14 Demo-
graphic data at the time of diagnosis (including sex, age,
smoking history), onset and outcome of acute exacerbation,
and number of times and timing of BAL procedures were
investigated from medical records. AE-IPF was defined using
the revised Japanese criteria for AE-IPF which states that all
of the following three conditions must be satisfied during the
course of IPFwithin a singlemonth: (1) dyspnea increases, (2)
new ground-glass opacities appear on HRCT in addition to
previous honeycomb lesions, (3) oxygen partial pressure in
resting arterial blood (PaO2) is lower by more than 10 mmHg
than previous measurements. Obvious causes of these
changes, such as infection, pneumothorax, cancer, pulmo-
nary embolism or congestive heart failure, were
excluded.15e17 Particularly in terms of excluding possibleinfection, following evaluation was routinely performed in
teria, fungi, and bacteria, assessment of serum titers against
Mycoplasma pneumoniae, Chlamydophila psittaci, Chlamy-
dophila pneumoniae, Legionella pneumophila, and various
viruses. In addition, excluding the possibility of infectionwas
made with additional BAL unless contraindicated.
The occurrence of AE-IPF within 30 days after BAL was
considered to be “BAL-induced AE-IPF.” BAL performed after
the onset of acute deterioration of respiratory status was not
included in this analysis. To test the hypothesis that devel-
opment of AE-IPF was more frequent after BAL procedure,
we set 30 days following the day of BAL as the period of risk.
To describe the risk from BAL of developing AE-IPF, the
person-month incidence rate for AE-IPF was calculated and
the incident rate ratio was determined as follows18: person-
month incidence rate of AE at risk (events per person-month)
is divided by person-month incidence rate of AE not at risk
(events per person-month). An incident rate ratio above 1
means AE is more likely to occur during the period at risk,
namely, during 30 days after BAL. The statistical significance
of an increased risk ratio was tested with two-sided Fisher’s
exact test. The follow-up time spanned the time from diag-
nosis of IPF until the onset of AE-IPF, death, or last contact,
whichever was earliest. The study protocol was approved by
the Ethics Committee of Tosei General Hospital.
In addition, published cases of AE-IPF that developed
after a BAL procedure were identified using computer
databases. We searched for similar reports published from
1985 through December 2009, using PubMed for reports in
English and Ichushi Web (http://www.jamas.or.jp) for
Japanese reports. Only published cases with detailed clin-
ical summaries were included in this review. Pertinent
clinical, laboratory and histological data were abstracted.
Result
Retrospective cohort study
Demographic and clinical data for the 112 patients enrolled
are shown in Table 1. The diagnoses of 53 cases (47.3%)
were pathologically confirmed with surgical lung biopsy.
During the median follow-up of 34.0 months, a total of 231
BAL procedures were identified. As shown in Fig. 1, thirty
BAL procedures were performed after the onset of acute
deterioration in order to rule out the possible complication
of infection.
During the follow-up, 60 patients (53.6%) died. Causes of
death were terminal respiratory failure in 25 cases, acute
exacerbation in 24 cases, infection in 4 cases, lung cancer
in 6 cases, and pneumothorax in 1 case. Among the 201 BAL
procedures performed in patients with stable condition,
four (2.0%) were followed by the onset of AE-IPF within
a month (crude incident rate: 19.9 per 1000 person-
months). The remaining 21 episodes of AE-IPF occurred in
patients not at risk (crude incident rate: 4.8 per 1000
person-months). The risk ratio was calculated to be 4.12
(95%CI Z 1.03e12.2, p Z 0.046) (Table 2).
All patients except one underwent BAL procedures at
the beginning of observation. None of the 111 initial BAL
procedures were followed by AE-IPF within a month.
Table 1 Characteristics of patients enrolled.
Total case 112
Sex, male/female 91/21
Surgically proven UIP, n (%) 53 (47.3%)
Age at baseline 64 (60e69)
Follow-up period, m 34.0 (21.7e53.8)
Death, n (%) 60 (53.6%)
Acute exacerbation, n (%) 25 (22.8%)
Number of BAL procedures, per patient 1 (1-2)
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before onset of AE
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before AE
Figure 1 Analysis profile ) reasons for exclusion were as follows
IPF by retrospective reconfirmation in this study, follow-up periods
patient enrolled in investigational treatment with agents with unp
438 K. Sakamoto et al.Therefore, we hypothesize that BAL performed as a second
round or later procedure might be strongly linked to
development of AE. We calculated the relative risk of
developing AE-IPF after second or later BALs which were
done in the course of IPF. The rate ratio was as high as 9.10
(95% CI Z 2.27e26.98, p Z 0.0032) (Fisher’s exact test)
(Supplemental Table1).
Summary of four cases of possible BAL-induced
AE-IPF
Four patients in our cohort developed AE-IPF during the 30
days following BAL. All four patients were men withth 
s”




fter onset of AE
(excluded from 
analysis)
IPF, excluded* N = 63
: did not completely fulfill the predefined diagnostic criteria of
were shorter than 6 months because of patient drop-out, and
ublished risk of development of AE.
Table 2 Estimation of relative risk of AE-IPF during 30 days after BAL procedure.
Event of AE Person-months Crude incident rate (event/person-month)
Post BAL (at risk) 4 201 0.0199
Not at risk 21 4344 0.0048
Relative risk 4.12 (95% CI Z 1.03e12.2, p Z 0.046) (Fisher’s exact test)
Temporal relationship between BAL and acute exacerbation of IPF 439a smoking history. They had experienced bronchoscopy and
BAL at least once prior to the causal BAL procedure.
Development of AE-IPF was diagnosed 12e30 days after
causal BAL. Diagnosis of AE-IPF was made with additional
BAL in all four cases in order to exclude possible infection,
and no viruses or microbes were detected. Treatment of AE
was done with high-dose corticosteroids (pulse therapy), in
some cases together with immunosuppressants and anti-
coagulants. Only one patient successfully survived AE and
was discharged from the hospital.
Review of the literature
We found 5 articles9e11,19,20 reporting cases of BAL-induced
acute exacerbation of IPF reported in the English or Japa-
nese language literature. From a review of the details of
cases with interstitial pneumonitis other than IPF, duplicate
reports of the same case and cases with insufficient data
were excluded. Finally, eight cases from four articles were
identified. Combined with our 4 cases, the clinical details
of the 12 detected cases of BAL-induced AE-IPF are
summarized in Table 3. Among them, nine patients had
decreased vital capacity (FVC < 65% predicted value) and/
or impaired gas diffusion capacity (DLco <50% predicted
value) at the time of causal BAL. Seven patients had either
elevated body temperature (>37 Celsius) or elevated
serum C-reactive protein above the normal value. Six
patients were treated with corticosteroids prior to causal
BAL. The intervals between causal BAL and diagnosis of AE
ranged from diagnosis immediately after the procedure to
41 days. Treatment for AE was done with high doses of
corticosteroids in all cases except one, in which treatment
was with antibiotics only and the patient recovered from
AE. In the end, only four of 12 patients survived the AE that
developed after a BAL procedure.
Discussion
In the present study, we demonstrated an increased risk of
acute exacerbation of IPF after BAL procedures in our
cohort. During the 30 days following a BAL procedure, the
risk for AE-IPF was estimated to increase about 4-fold. It is
also worth noting that no AE-IPF was experienced after BAL
procedures done for an initial diagnosis, and therefore
subsequent BAL procedures were estimated to be a higher
risk. In addition, possible denominators of AE-IPF following
BAL were indicated from analysis of pooled cases that
included the four cases from our cohort and eight from the
literature review. We should beware of the possibility that
BAL may predispose IPF patients to the development of AE,
and carefully consider its indication on the basis of indi-
vidual cases.To our knowledge, this was the first study to evaluate
the risk from BAL for the onset of AE-IPF in terms of the
temporal relationship. Several reports have described cases
of acute deterioration of idiopathic interstitial pneumonias
including IPF, as shown in Table 3. A recent systematic
review13 citing these reports, also mentioned the possibility
that BAL may become a trigger of AE-IPF. However, previous
studies could not quantify the relative risk of BAL in trig-
gering acute exacerbation because of the lack of sufficient
information on the population and/or period of
observation.
In our cohort the diagnosis of IPF was made in accor-
dance with ATS/ERS classification.14 Patients were carefully
examined if they met criteria for other disease entities.
Furthermore, diagnosis of AE-IPF was made with certainty
according to the criteria described above. In our cohort the
1-year frequency of AE was estimated to be 6.3%, which
was consistent with previous reports that demonstrated the
1-year frequency is around 5e10%.11,16
Focusing on the condition at the time when AE-IPF after
BAL occurred, it is worth noting that none of the patients
developed AE after the BAL procedures done for initial
evaluation. To determine whether there are any common
factors, we examined the clinical characteristics of 12
pooled cases with AE-IPF following BAL from our cohort and
the previous literature. A previous study21 gave the
following three features as evidence of objective impair-
ment for classifying the severity of disease: (1) FVC < 65%,
(2) desaturation with exertion, (3) DLco  50%. By adopting
these criteria, we tried to classify the severity of functional
impairment of eleven cases whose pulmonary function data
just before BAL were available. Although we could not
retrieve the data on exertional desaturation, 9 out of 11
cases were classified as having at least “moderate” or
“severe” impairment. Similarly, marginal hypoxemia (less
than 70 torr in PaO2) was observed in 7 out of 12 cases. The
patients who developed AE after BAL tended to have
certain functional impairment before BAL procedures. This
is compatible with recent studies evaluating risk factors for
AE-IPF that reported low FVC is a significant predictor of
AE-IPF.17,22 Another noteworthy aspect is the “unstable-
ness” of the disease. Elevated CRP level (>1 mg/dL) and/or
increased WBC count (>9000/mm3), which is unusual with
stable IPF, were observed in six cases. Increased neutro-
phils in BALF (>10%) were identified in 2 other cases.
Moreover, 6 out of 12 patients had received corticosteroid
treatment before AE, which was possibly aimed at halting
the accelerated progression of the disease. These results
suggest the possibility that, in at least some of the cases,
insidious infection or deterioration of the disease may exist
before BAL, rather than that BAL itself causes AE. A recent
report that demonstrated disease progression, defined by
at least a 10% decline in FVC, was a risk factor for AE-IPF
Table 3 Cases in which acute exacerbation of IPF developed after BAL: Summary of our cohort and literature review.









Pa02 BT CRP WBC TCC Ne Ly Eo
Torr C mg/dL /mm3 106/ml % % %
Our institution 51/M þ 44/57 65.7 36.5 1.6 2800 CS 18 1.4 4 1.7 0.3 Pulse Died 47d after BAL UIP/DAH
68/M þ 46/38 75.8 36.3 0.4 6800 CS 15 9.9 0.3 3 0.2 Pulse CyA, LMH Died 26d after BAL UIP
64/M þ 75/20 51.0y 38.5 4.6 15100 Abs 12 16 0.8 0.2 0.2 Pulse CyA Survived AE 
70/M þ 63/40 68.5 afebrile 0.1 5600 CS 30 1.3 0.2 0.3 0.3 Pulse LMH Died 80d after BAL UIP
Yoshitomi
et al.(16)
54/F  43/n.a. 77.3 37.4 0.6 6100 Abs 0 1.3 6.5 5.4 1.5 Pulse CPA Died 34d after BAL UIPþDAD
75/M þ n.a. / n.a. 63.5z 38 (3þ) 9800 none 0 2.7 35 8.8 2.8 Only bs Survived AE 
Suga et al.(10) 67/M þ 60/31 65 36.7 0.1 8700 CS 41 10 11 46 0 Pulse Died 17d after BAL DAD
57/M þ 53/16 61.3 35.9 6.7 13800 CS 3 10 4.8 2.6 0 Pulse Died 6d after BAL 
Hiwatari
et al.(9)
74/M  60/n.a. 82 afebrile () n.a. CS n.a. 1.5 4 10 0 Pulse PSL Died 18d after BAL UIP?
66/M þ 65/41 65 afebrile (þ) n.a. none n.a. 0.8 30 2 1 Pulse PSL Died 104d after BAL UIPþDAD
79/F  99/58 80 afebrile 1 n.a. none n.a. 5.6 2 3 3 Pulse PSL Died 56d after BAL UIP?
Ohtsuka
et al.(17)
74/M þ 97/52 84.1 afebrile 0 6600 none 7 n.a 14 31 2 Pulse Abs Survived AE 
BT: body temperature, WBC: white blood cell count, previous BAL: number of BAL procedures done before, TCC: total cell counts, Ne neutrophils; Ly: lymphocytes, Eo: eosinophils, CS:
corticosteroids, Pulse: corticosteroid pulse therapy, d: day, CyA: cyclosporine A; LMH: low molecular weight heparin, CPA: cycloph sphamide, Abs: antibiotics, UIP: usual interstitial
pneumonia pattern, DAH: diffuse alveolar hemorrhage, DAD: diffuse alveolar damage pattern, n.a.: not available.
y Assessed under 3 L/min of supplemental oxygen via nasal prongs.
























Temporal relationship between BAL and acute exacerbation of IPF 441supports this speculation.17 Considering that the relative
risk of developing AE after second or later BAL procedures
was estimated to be considerably higher (although in a post
hoc analysis), patients should be more carefully monitored
after BAL performed during the course of IPF than after BAL
performed in initial evaluation.
There is some speculation on the possible mechanism
responsible for the development of AE-IPF after BAL. The
first is that BAL might spread subclinical infection in the
lower respiratory tract. In cases of IPF, especially with
administration of corticosteroids and/or immunosuppres-
sants for its management, it is possible that certain path-
ogens colonize the lower respiratory tract of the patients
and that many of these immunosuppressed patients fail to
develop typical clinical signs. Contamination by pathogens
or endotoxins through working channels of bronchoscopes is
also possible.22,23 In our series, however, no pathogen or
endotoxin was detected from BAL fluid obtained at the
diagnosis of AE-IPF.
Another speculation is that saline lavage itself may
cause lung injury. Repeated bronchoalveolar lavage with
saline has been utilized in making an animal model of acute
lung injury.24,25 Lavage with saline reduces the surfactant
lipid concentration in alveolar lining fluids, altering alve-
olar surface tension. Decreased alveolar tension may
facilitate alveolar collapse and increase the likelihood of
mechanical injury to the alveolar walls during ventilation.
Impaired alveolar host defenses caused by decreased
surfactant proteins also may predispose patients to lung
injury. In patients with pulmonary fibrosis or even in
healthy subjects, there is evidence that proinflammatory
cytokines such as IL-1-b and TNF-a increase in serum or BAL
fluid after BAL procedure.26,27
This study has some limitations. It was based on
a retrospective cohort from a single institution which
includes only Asian patients. Ethnic differences in the
incidence of pulmonary disease have been observed and
ethnic difference in the susceptibility to AE-IPF is also
suggested.28 It is unclear whether the present results can
be adapted to other populations, especially to other ethnic
groups. Multicenter- multiregional- prospective studies are
warranted to eliminate ethnic bias and other possible bias.
Moreover, whether there was causal association between
BAL and onset of AE-IPF could not be determined because
the current study evaluated the temporal relationship only.
Although we acknowledge that other confounding
factors exist (e.g. unrevealed infections, change in medi-
cations, patients’ baseline characteristics), other risk
factors for the development of AE-IPF remain largely
unknown. In the context that confounders were assumed to
be impossible to eliminate, we believe it is still of value to
specify the relative risk within 30 days after BAL
procedures.
In this study we adopted revised Japanese criteria in
diagnosing AE-IPF. The AE/IPF criteria are different in the
other studies, though they are largely similar. One of the
reasons is the current official ATS/ERS/JRS/ALATguideline of
IPF did not define the criteria of AE.29 Because development
of acute exacerbation is being recognized as one of the most
important outcomes in patients with IPF, further investiga-
tion is warranted to unify the AE-IPF criteria internationally
in order to clarify the epidemiology of AE-IPF.In summary, we investigated the temporal relationship
between bronchoalveolar lavage and development of acute
exacerbation in idiopathic pulmonary fibrosis. About a 4-
fold increased risk of AE within 30 days after BAL was
observed during the follow-up of 112 IPF patients and risk
was estimated to be greater with BAL procedures done in
second or later rounds in the course of the disease. Since
many confounding factors may be present in the clinical
setting, it remains uncertain whether BAL predisposes
patients to the development of AE-IPF. Although further
large-scale prospective studies are warranted for firm
conclusions, our current results suggest that IPF patients
should be carefully monitored after a diagnostic BAL
procedure.
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